A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma

Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
PLoS Medicine (Impact Factor: 14.43). 07/2010; 7(7):e1000307. DOI: 10.1371/journal.pmed.1000307
Source: PubMed


Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease. For patients with localized PDAC, surgery is the best option, but with a median survival of less than 2 years and a difficult and prolonged postoperative course for most, there is an urgent need to better identify patients who have the most aggressive disease.
We analyzed the gene expression profiles of primary tumors from patients with localized compared to metastatic disease and identified a six-gene signature associated with metastatic disease. We evaluated the prognostic potential of this signature in a training set of 34 patients with localized and resected PDAC and selected a cut-point associated with outcome using X-tile. We then applied this cut-point to an independent test set of 67 patients with localized and resected PDAC and found that our signature was independently predictive of survival and superior to established clinical prognostic factors such as grade, tumor size, and nodal status, with a hazard ratio of 4.1 (95% confidence interval [CI] 1.7-10.0). Patients defined to be high-risk patients by the six-gene signature had a 1-year survival rate of 55% compared to 91% in the low-risk group.
Our six-gene signature may be used to better stage PDAC patients and assist in the difficult treatment decisions of surgery and to select patients whose tumor biology may benefit most from neoadjuvant therapy. The use of this six-gene signature should be investigated in prospective patient cohorts, and if confirmed, in future PDAC clinical trials, its potential as a biomarker should be investigated. Genes in this signature, or the pathways that they fall into, may represent new therapeutic targets. Please see later in the article for the Editors' Summary.

Download full-text


Available from: Jeran Stratford,
  • Source
    • "Many of the altered biological pathways in PDXs are typically deregulated in metastatic tumors compared with primary tumors. In fact, it has been proposed that PDX models mimic aggressive and/or metastatic tumors derived from the original primary tumors [42,46,54]. The tumor engraftment could be seen as a 'forced' metastatic situation, because the tumor needs to colonize a new environment to survive. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Engraftment of primary pancreas ductal adenocarcinomas (PDAC) in mice to generate patient-derived xenograft (PDX) models is a promising platform for biological and therapeutic studies in this disease. However, these models are still incompletely characterized. Here, we measured the impact of the murine tumor environment on the gene expression of the engrafted human tumoral cells. We have analyzed gene expression profiles from 35 new PDX models and compared them with previously published microarray data of 18 PDX models, 53 primary tumors and 41 cell lines from PDAC. The results obtained in the PDAC system were further compared with public available microarray data from 42 PDX models, 108 primary tumors and 32 cell lines from hepatocellular carcinoma (HCC). We developed a robust analysis protocol to explore the gene expression space. In addition, we completed the analysis with a functional characterization of PDX models, including if changes were caused by murine environment or by serial passing. Our results showed that PDX models derived from PDAC, or HCC, were clearly different to the cell lines derived from the same cancer tissues. Indeed, PDAC- and HCC-derived cell lines are indistinguishable one from the other based on their gene expression profiles. In contrast, the transcriptomes of PDAC and HCC PDX models can be separated into two different groups that share some partial similarity with their corresponding original primary tumors. Our results point to the lack of human stromal involvement in PDXs as a major factor contributing to their differences with the original primary tumors. The main functional differences between pancreatic PDX models and human PDAC are the lower expression of genes involved in pathways related to extracellular matrix and hemostasis and the up regulation of cell cycle genes. Importantly, most of these differences are detected in the first passages after the tumor engraftment. Our results suggest that PDX models of PDAC and HCC retain, to some extent, a gene expression memory of the original primary tumors, while this pattern is not detected in conventional cancer cell lines. Expression changes in PDXs are mainly related to pathways reflecting the lack of human infiltrating cells and the adaptation to a new environment. We also provide evidence of the stability of gene expression patterns over subsequent passages, indicating early phases of the adaptation process.
    Genome Medicine 04/2014; 6(4):27. DOI:10.1186/gm544 · 5.34 Impact Factor
  • Source
    • "K-ras, TP53, SMAD4, p16, Plectin-1, Caveolin-1, hENT1, miR-216, miR-217, miR-196, miR-196a, miR-186, miR-222, miR-200b, miR-15b, miR-95, FosB, KLF6, ATP4A, NFKBIZ, GSG1, SIGLEC11 [22] [43] [84] [85] [100] [125] [131] [213] [214] [215] [216] [217] [218] [219] [220] Pancreatic juice Quantitative proteomics AGR2, S100A6, MMP-9, DJ-1, A1BG, MMP-7, miRNA-21, miRNA- 155, Twist, PRSS2, PLRP1, hTERT [72] [166] [221] [222] [223] [224] [225] [226] Serum Quantitative proteomics, ELISA, CA 19-9, CA 125, CEACAM1, MMP-7, REG4, HSP-27, IGF, IGFR, cyclin I, GDI2, PF4, SAA, fibrinogen [37] [50] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] Plasma Functional genomics TNC, TFP1, TGFBI, SEL-1L, LICAM, WWTR1, CDC4BPA, CK 18 [101] [237] CTC RT-PCR C-MET, h-TERT, CK20, ELC, PlGF [238] [239] Saliva Human genome array K-ras, MBD3L2, ACRV1, DPM1 [80] Stool PCR K-ras, TP53 [81] [240] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The lack of early symptoms results in latestage detection and a high mortality rate. Currently, the only potentially curative approach for PC is surgical resection, which is often unsuccessful because the invasive and metastatic nature of the tumor masses makes their complete removal difficult. Consequently, patients suffer relapses from remaining cancer stem cells or drug resistance that eventually lead to death. To improve the survival rate, the early detection of PC is critical. Current biomarker research in PC indicates that a serum carbohydrate antigen, CA 19-9, is the only available biomarker with approximately 90% specificity to PC. However, the efficacy of CA 19-9 for assessing prognosis and monitoring patients with PC remains contentious. Thus, advances in technology and the detection of new biomarkers with high specificity to PC are needed to reduce the mortality rate of pancreatic cancer.
    Current pharmaceutical design 02/2012; 18(17):2439-51. DOI:10.2174/13816128112092439 · 3.45 Impact Factor
  • Source
    • "Given the high morbidity and mortality rates associated with PC, there is an urgent need to develop specific, sensitive and cost effective biomarkers of clinical importance that can help inform treatment decisions thus improving the survival outcomes of PC patients. Various " omics " technologies (genomics, transcriptomics, proteomics ) have been used for biomarker discovery of pancreas cancer [4] [5] [6] [7]. As the downstream complement to the other " omics " , metabolomics is the comprehensive analysis of small molecule metabolites produced by normal or abnormal cellular processes. "
    [Show abstract] [Hide abstract]
    ABSTRACT: a b s t r a c t Pancreatic cancer (PC) is the fourth leading cause of cancer death in the United States, with 4% survival, 5 years after diagnosis. Patients with pancreatic cancer are usually diagnosed at late stages, when the disease is incurable. Sensitive and more specific markers are critical for supporting new prevention, diagnostic or therapeutic strategies. Here, we report mass spectrometry-based metabolomic profiling of human pancreas matched tumor and normal tissue. Multivariate data analysis using two independent methods shows significant alterations in the profiles of the tumor metabolome as compared to the normal tissue. These findings offer an information-rich matrix for discovering novel candidate biomarkers with diagnostic or prognostic potential.
    International Journal of Mass Spectrometry 01/2012; 310:44-51. DOI:10.1016/j.ijms.2011.11.005 · 1.97 Impact Factor
Show more